Biocom Lifelines - Spring 2015

10

Nudging Out 2014, Sweeping In 2015

20 LifeLines

Come Ignite Your Love for STEM

18

Biocom Your Move

NG I T

A

RS

CEL E

BR

A

For the Southern California Life Science Community

17

YE

IT WAS TWENTY YEARS AGO: BIOCOM LOOKS BACK AND AHEAD

VOLUME 24, ISSUE 1 S p r i n g 2 0 1 5

Dexcom, Inc.

AltheaDx

218,000 SF Tenant Representation

Arcturus Therapeutics

60,000 SF Tenant Representation

Exterior View @ South Facade TORREYANA

San Diego, CA

Biocom

10,000 SF Tenant Representation

10,900 SF Tenant Representation

Cubist

Genomatica

45,000 SF Sublease Disposition

Verenium / BASF

70,000 SF Tenant Representation

70,000 SF Tenant Representation

April 3, 2013

Mirati Therapeutics 18,000 SF Tenant Representation

Genzyme / Sanofi 64,000 SF Sale Disposition

WELCOME

IN THIS ISSUE 2

By Joe Panetta, President and CEO, Biocom

Cover Story: It Was Twenty Years Ago: Biocom Looks Back and Ahead

Biocom Timeline: Looking back 20 years 8-9 10 Public Policy : Nudging Out 2014, Sweeping In 2015

11 Guest: The Biocom CRO Group: Transforming San Diego’s Life Sciences Outsourcing Industry

12 Guest: Venture Capital Outlook Optimistic as IPO, M&A Streaks Continue

CELEBRATING 20 SUCCESSFUL YEARS Welcome to our first edition of LifeLines for 2015, celebrating Biocom’s 20th anniversary year as the voice of Southern California’s life sciences industry. As I complete this column, Biocom’s new offices have just been completed in the ARE Life Science Industry Community Center on Torrey Pines Mesa. My team and I look forward

14 Guest: A forum on the business of outsourcing is

to maintaining a strong relationship with our members on the Mesa, and welcoming

16 Biocom Institute: What are We Doing Now? 17 Science Festival: Come Ignite Your Love for STEM 18 Purchasing Group: Biocom Your Move 20 Premium Member Spotlights:

art building, which will allow us to more effectively network and advocate for our

coming to San Diego

EY, Pfizer, Latham & Watkins, Wilson Sonsini Goodrich & Rosati

22 Biocom Board and Committees 23 Biocom Membership

members and visitors from throughout the region and the world to this state-of-the community.

Our cover story this month looks back on 20 years of Biocom history – where we were then and how far we have advanced today to become the largest regional life science association in the world. Written by former Biogen Idec director of Investor Relations and Communications Vince Reardon, it provides a unique perspective from a 30-year San Diego life sciences veteran.

With Biocom’s continued strong efforts in public policy on the local, state and national level in full swing, this issue reviews our recent roundtable with San Diego Mayor Kevin Faulconer; our January life sciences briefing with members of the State Legislature, including Assembly Speaker Toni Atkins and Select Committee on Biotechnology Chair, Assembly Member Kevin Mullin; the digital health members fly-in

E D I TO R : Jennifer Landress CO P Y E D I TO R : Josh Baxt DESIGN & LAYOUT: Arlene Arreola

hosted by our Washington, D.C., office; and a look ahead at the 21st Century Cures legislative package.

Our key Biocom initiatives all continue to grow and you will read about several of them here. Our CRO initiative has its own web site at biocomcro.org, and this month Biocom board and executive committee member Tim Scott, who chairs the initiative,

VOLUME 24, ISSUE 1

will tell you more about CROs in Biocom. Our San Diego Festival of Science & Engineering, which focuses on making teachers, students and parents more aware of career opportunities in the field, will be held this March. In this edition, you will learn more about what to expect at the event. And speaking of events – another strength of Biocom over the last 20 years – this month we feature a guest article from Life Science Leader magazine, our partner on the conference this August called Outsourced Pharma West.

Biocom, a member driven organization is here to assist life science companies like yours to fulfill your most ambitious goals. We can help your company with saving money, advocacy, increased visibility, networking opportunities, capital development and workforce development.

As if that is not an aggressive enough agenda, we also feature articles on the other important pillars of Biocom. Our Biocom Institute has exciting plans for this year, including our Festival, as well as a Veterans Training Program, a Teacher Fellows Program and the return of our STEM Voice Video competition. The Biocom Purchasing Group, which has increased its offerings to our members significantly over the past year, reviews a new program called, Biocom Your Move Program, which pulls together a number of different vendor contracts to collectively assist in your facility move.

Please enjoy this anniversary issue and come by to see us in our new facility as we continue to accelerate the success of the regional life sciences industry.

WWW.BIOCOM.ORG Biocom LifeLines Spring 2015

1

CELEBRATING

20 ye a r s

S U C C E S S t h r o u g h COMMUNITY

#Biocom20

COVER STORY

By Vince Reardon

It Was Twenty Years Ago: Biocom Looks Back and Ahead Opportunity comes in many disguises and loiters at the most unlikely crossroads. In 1991, San Diego was in the grip of a long and severe drought. The San Diego City Council and Mayor Maureen O’Connor were struggling to find ways to conserve water. One plan was to impose draconian water rationing measures on local manufacturers. The proposal --GREG LUCIER, FORMER called for some companies to get water in the morning, others in the afternoon.

OF LIFE TECHNOLOGIES The organization that would ultimately becomen Biocom was conceived during this crisis.

“Things were looking pretty bleak,” said Guy Iannuzzi, president of Mentus.

“Obviously, the council didn’t know about the industry’s need for water.”

David Hale, then president of Gensia and the former president of Hybritech, became the spokesperson for the industry.

Everybody knew him.

Hale said: “This is nonsense! We can’t live with this. We’re going to change it.’ He called other CEOs in the industry and some of the service providers together – lawyers, architects, and commercial real estate agents – and said, “We have to go to the City Council and tell them this isn’t going to fly.”

Hale got then-Councilman Ron Roberts CHAIRMAN AND CEO to schedule a biotech day with the City Council. “I made a presentation on behalf of the industry and we had four companies that talked about the industry, about what they were doing,” said Hale, now Chairman and CEO of Hale BioPharma Ventures, LLC. “It was about a three hour session.

The Council had no idea what the industry was doing. But the important thing that came out of it was the council appointed a special liaison, an ombudsman, within the city government to work on our issues. That was a real success.”

The mayor and the council got the message and scuttled the water rationing plan. “After that meeting, I pulled together the same group and started the Biotechnology Industry Council (BIC),” Hale said. BIC consisted primarily of biotech CEOs, such as Bill Rastetter, the late Duane Roth, Howard Birndorf and included the late Bill Otterson of UCSD Connect.

“WITHOUT BIOCOM, SAN DIEGO WOULDN’T BE THE LIFE SCIENCES HUB THAT IT IS.”

2

Biocom LifeLines Spring 2015

An Industry in Search of an Organization “The industry became self-aware,” Iannuzzi said. “From that

COVER STORY moment, we realized we could speak to the community and the community would listen.

We could affect a change.”

As BIC was taking shape, the late Jim McGraw of McGraw/Baldwin Architects, Wain Fishburn, now of Cooley LLP, Brent Jacobs, now of Cushman Wakefield, and Iannuzzi created a second organization, called the San Diego Biocommerce Association.

“The operating theory was that this group could lobby more effectively and with less exposure or risk than the biotech companies,” said Ken Baldwin of Ferguson, Pape Baldwin Architects.

BIC and the San Diego Biocommerce Association existed as parallel organizations for about four years, until members of both groups recommended consolidation. But what to call the new organization?

“I suggested abbreviating the San Diego Biocommerce Association to simply Biocom,” said Baldwin. “It had a nice ring to it.”

The new name was chosen to suggest bio-commerce, biocommunication, and bio-community. The name was quickly adopted and has been widely embraced ever since.

Ironically, what began as an informal committee united behind one issue – water – evolved into an official organization in May 1995 with one common vision and purpose: to promote and support life science companies in the region. Duane Roth was named the first chairman of Biocom and Ann Randolph the first managing director.

In 1999, the board recruited Joe Panetta, formerly the vice president of government and public affairs at Mycogen, to serve as Biocom’s first President and CEO. Under Panetta’s skillful stewardship Biocom has developed programs that have delivered, and in some cases anticipated, members’ needs in five key areas: capital development, public policy, professional networking and communications, group purchasing and workforce development.

Capital Development Even before the merger of BIC and the San Diego Biocommerce Association, the two groups were working together to bring investors to San Diego. In 1992, they organized the first CalBio Summit to showcase the sector to venture capitalists, Wall Street investors and distinguished elected officials, including then Governor Pete

Wilson.

Over the years the CalBio Summit, now called CALBIO, has grown in size and stature. “It’s truly a statewide conference today,” said Carin Canale of Canale Communications. “If you’re a biotech entrepreneur in California and you only attend one conference throughout the year, from an education, partnering and networking perspective, CALBIO is the one to attend.”

For example, the last CALBIO in 2013 attracted numerous venture capitalists from the Bay Area, as well as potential partnering companies from the both coasts, including Eli Lilly, Pfizer, Sanofi and Johnson & Johnson.

Last year, there was no CALBIO. Instead, Biocom hosted the 2014 BIO International Conference in June and achieved record attendance. More than 15,000 industry leaders, including nearly 2,500 CEO’s from 50 states and 70 countries attended.

The convention featured keynotes from Sir Richard Branson and former Secretary of State Hillary Rodham Clinton. In addition, there were more than 800 speakers and 160 sessions in eight educational tracks and nine specialty forums, which addressed the latest business opportunities, breakthroughs in medicine, diagnostics, the environment, energy production, food and agriculture and more.

“Biocom’s strength and depth in capital development has grown tremendously,” said Canale.

“In addition to “Venture Speed Dating” during CALBIO, several times a year we invite out-ofmarket venture capitalists to San Diego to meet with companies.

Recently we had Canaan Ventures, InterWest Partners and Fraiser Ventures all in the room at the same time. To get funds collectively worth a couple of billion dollars to come to San Diego and spend the day with emerging companies is hard to come by and a true value-add to Biocom members.”

In recent years, these meetings have produced significant financial transactions for local life science companies. “In the last two years (2013-14), we’ve seen an incredible number of company creations, financings, successful exits, such as initial public offerings (IPOs), as well as acquisitions, which have been unprecedented in our industry” said Magda Marquet, Ph.D., founder and co-chairman of Althea Technologies. “The climate has been very, very healthy financially.”

Biocom LifeLines Spring 2015

3

COVER STORY Professional Networking and Communications Public Policy As the life sciences industry has matured over the past 20 One of the major roles Biocom has played over the last 20 years years, Biocom has become the premier organization in the region, has been shaping public policy locally, regionally and nationally. bringing interested parties together from “The breadth of public policy support all sectors of the community: public Biocom provides the industry has always and private companies, research and been impressive,” said Baldwin. “For educational institutions and government example, it has a political action committee agencies. and a significant lobbying presence in “When I came to San Diego 16 years ago, both Sacramento and Washington, D.C. It I was new to the West Coast,” said Alex didn’t take too many instances of ‘We’re --MAGDA MARQUET, CO-FOUNDER, ALTHEA (A Lukianov, Chairman and CEO of Nuvasive. not getting what we want out of these MEMBER OF THE AJINOMOTO GROUP) “Biocom was terrific from the standpoint of processes’ to create a structure to address networking in those early days, especially it, and usually in advance of when the getting to know the community and meeting people on the Biocom actual need was there.” board. Over the years that’s blossomed into a series of professional Forward thinking and political action paid dividends in 1993friendships with local company CEOs and VCs. I have always been 94 when the Clinton Administration was promoting its health care plan. “We went back to Washington, D.C., half a dozen times with Biocom and Connect,” said Hale. “We met with Ira Magaziner, the administration’s health care czar, as well as Hilary Clinton, on the health care bill.”

By 1994 Senate Majority Leader George Mitchell declared the Health Security Act dead, following withering criticism from the biopharmaceutical industry, with input from Biocom, as well as the business sector in general.

“Besides successes in Washington, D.C., Biocom has also been very effective at the state level, working with legislators and Governor Brown on issues that affect our industry and the state,” Hale said.

Over the years, the issues have ranged from successfully advocating for elimination of duplicative state inspections of facilities already inspected by the Food and Drug Administration (FDA), to enactment of industry-specific state sales tax relief for equipment used in pleased with Biocom’s networking capabilities.” research and Biocom also provides tools and resources for entrepreneurs in development, life sciences. “These can range from mentoring help in getting to ongoing capital, to assistance with outsourcing needs, to having your voice monitoring and heard in Washington or Sacramento,” said Marquet. “Biocom has lobbying when not only grown with the industry, it has also anticipated the needs state legislation of the industry. That’s impressive.” has unintended consequences for Group Purchasing the life sciences Since its inception, Biocom has been able to deliver significant industry. savings to members on the purchase of supplies and equipment. “If Meanwhile, you look at the benefits of Biocom’s Purchasing Group, it’s simple Biocom remains statistics,” said Baldwin. “Everyone understands hard numbers. If actively involved you join Biocom, you’re going to save tens of thousands of dollars in local issues critical to the industry. “Biocom has worked with or more, depending on your scale.” the Mayor’s office to add a quarterly roundtable discussion,” said There are more than 40 member vetted contracts endorsed Canale. “On a quarterly basis we meet with the mayor and his team

by Biocom, which translate into significant volume savings and to discuss life sciences and what the city can do to continue to favorable terms on products and services frequently used in the support one of the driving forces of the San Diego economy.”

“BIOCOM HAS NOT ONLY GROWN WITH THE INDUSTRY, IT HAS ALSO ANTICIPATED THE NEEDS OF THE INDUSTRY. THAT’S IMPRESSIVE.”

4

Biocom LifeLines Spring 2015

COVER STORY industry stay up-to-date as employment trends and industry needs change. “San Diego is building this incredible combination of basic research, drug development capabilities and now increasingly – with all the medical center building going on – a place to be treated as well. San Diego is becoming not only a life sciences hub but also a healthcare hub,” said Greg Lucier, former chairman and CEO of Life Technologies.

life science industry. “If you don’t join Biocom, it’s not because of membership cost,” said Baldwin. “There is a direct offset available to you if you use the Purchasing Group.”

Workforce Development For years Biocom has been in the forefront of helping companies develop the skills of their employees. Sixty-one percent of all jobs in California, approximately 12 million jobs, will require some post-secondary training beyond high school in 2018, according to workforce development experts. Biocom is out in front of those numbers by supporting local educational institutions.

“We have a wonderful workforce opportunity in our region,” Canale said. “We have institutions of higher education that are flexible and forward-thinking in the degrees they offer students. In addition, Mira Costa Community College and Palomar College offer various technical, biomedical and bioprocessing certificates that prepare students for real jobs in life sciences labs.”

In addition, the Biocom Institute offers various professional development programs, such as a management training certificate through the Leadership Edge, networking and professional development for women in the life sciences through Women in Bio and presentation training through 2Connect.

There are also Biocom Institute programs to strengthen proficiency in science, technology, engineering and math (STEM) in our city schools, such as the annual San Diego Festival of Science & Engineering and the Teacher Fellows program exposing K-12 STEM Educators to the life science industry. And there are training and technical programs to support returning veterans from Iraq and Afghanistan, such as the existing veteran career mentoring program and Fatigues to Lab Coats, a program in development that will train veterans to be bio technicians.

Biocom’s workforce development is helping the life sciences

6

Biocom LifeLines Spring 2015

Looking Ahead “Biocom is a tremendous success story because of its central focus on the life sciences ecosystem, because of its strong leadership under Joe Panetta, and because of the broad participation of its member companies, which have allowed San Diego to become the place to practice life sciences,” said Lucier. “Without Biocom, San Diego wouldn’t be the life sciences hub that it is.”

So what can one expect from Biocom in the years ahead? Look for continued support of existing programs and the initiation of a wide range of new programs and activities supporting the regional life science industry on a global scale.

For starters, San Diego is truly the world leader in the exciting area of genomics and Biocom is working diligently to support this new growing sector. “In San Diego you have Illumina and other genomics companies, like Sequenom, Edico Genome and BioNano,” said Canale. “Then, you have Dr. Eric Topol at Scripps Research Institute. You have the Moores Cancer Center, which is saying it’s going to sequence every cancer patient that walks through the door. And of course, there’s Craig Venter, who sequenced the human genome. When he wanted to build his research institute, where did he come? He came to San Diego.”

Biocom is also supporting the emerging convergence of life sciences and wireless technologies.

“When Biocom started, its focus was addressing the needs of drug development companies,” said Marquet. “Then, it became diagnostics and medical devices. Later, it reached out to industrial biotechnology companies. Now it’s digital health, mobile health, which is really growing. San Diego is the capital of wireless health in the world. By incorporating this growing area into Biocom, I think we respond to the current needs and future needs of the industry.”

Biocom is also promoting the maturation of medical device companies in the region. “We’ve been a little bit of a well-kept secret for many years – well known for biotech, not so much for medical device companies,” said Lukianov. “But I think that’s changing. As I contrast the last decade with the prior decade, I would say things have dramatically improved relative to our stature

in San Diego as a biotechnology, medical device, life sciences community. I think going forward that is only going to get better because we have a great brain trust here.”

Biocom will also continue to look for opportunities abroad.

While its focus is principally local and regional, it frequently travels abroad to lure foreign companies and investors to the local life sciences community. “In the last few years, Joe Panetta and a delegation of Biocom board members and CEOs have worked to grow Biocom and San Diego’s reputation across Asia,” said Canale. “Because of this tireless work, we are largely considered the example to follow when it comes to building life science regions or the partner of choice for companies looking to build trans-Pacific relationships.”

Biocom has conducted four trade missions from 2009 to 2012 and has established new relations within China’s emerging life sciences industry. It has also introduced Biocom members to their counterparts in China. After visiting France and Japan last year, Biocom welcomed companies from both countries into its membership. In addition, Biocom has signed MOU’s with these

respective regions to futher opportunities for members to engage with International groups.

Peter Drucker said: “To build achieving organizations you must replace power with responsibility.” From its earliest days, that’s what the two organizations that merged into Biocom did so successfully. Instead of bickering and posturing, the pioneers of Biocom rolled up their sleeves and responded to an existential threat – a drought.

But could anyone have predicted the organization’s success over the past 20 years? “No, I don’t think anyone could have had that vision,” said Hale. “I did think that it was something that we would continue to need because there are a lot of issues that come up that are very difficult for one company to tackle. I did feel from the very beginning that having an organization that represented the industry here in San Diego was going to be very important and sustainable and could continue to have an impact.”

Vince Reardon is a freelance writer in San Diego. He is the author of the recently published The Pocket Mentor: Insider Tips from America’s Most Successful Americans.

Atheln is a Contract Development Organization delivering solutions to biopharma companies Innovative virtual product development approach Multidisciplinary strategy and plans from early stage to exit Team of industry seasoned experts excel in delivering solutions for risk control Integration of technical and commercial considerations to maximize product value

www.athelnbiomed.com

CELEBRATING

20 ye a r s ‘95

‘96

BIC and San Diego Biocommerce Association vote to merge as BIOCOM/San Diego.

‘08 The Biocom Institute is created.

‘09 Biocom plays a critical role in passage of California’s adoption of an optional single sales factor corporate income tax apportionment so that companies are no longer penalized for the size of their CA payroll.

‘07 Launched a career site, a job site exclusively for Southern California companies.

‘10 Biocom and key members come together to create the CRO Initiative. www.biocomcro.org.

Biocom Purchasing Group created.

‘06 Launched the Capital Development Initiative and hosted the 1st Annual Investor Conference.

‘11 Launched the 1st Annual Global Partnering Conference focused on bringing together top licensing and BD professionals from around the globe to a two day conference in San Diego.

‘97 Launched the scholarship and education fund.

‘05 Retained Sloat, Higgins, Jensen & Associates as its Sacramento lobbying firm, giving it a constant, on the ground presence in the state capitol for the first time.

‘12 The San Diego Festival of Science & Engineering finds its new home in Biocom.

‘98 1st Annual Life Sciences Night at the Opera event.

‘99 Joe Panetta joins as President and CEO.

‘04

Opened a full time Washington DC Office.

Biocom was instrumental in supporting the Governor’s economic development package, which, among other things, exempted equipment used in R&D from state sales tax.

Hosted the 1st Annual Nobel Laureate Dinner to honor the six Nobel Prize winners in chemistry, physiology and medicine who live in San Diego.

‘03

The passage of Prop. 71 which provided $3 billion funding for embryonic stem cell research in CA over ten years.

‘13

‘00

‘14 The launch of BiocomConcierge.com – a web site that connects member needs with the services of a fellow Biocom members.

First Biocom Annual Dinner with keynote speaker Naomi Judd.

‘01 The world’s biotechnology convention converges on San Diego for BIO 2001.

‘02 Opened an office in Carlsbad, recognizing the need to focus on life science companies in North County.

‘15 Relocated to our permanent home on the Torrey Pines Mesa and celebrates 20 years of being the accelerator for the life sciences industry in Southern California

PUBLIC POLICY

By Jimmy Jackson, Senior Vice President of Public Policy, Biocom

Nudging Out 2014, Sweeping In 2015 As we begin 2015, new delegations have been seated at the federal, state and local levels of government. With that comes the responsibility of educating a whole new group of policy-makers about the life sciences industry and its importance to the Southern California economy. The faces change, but some of the legislative fights of 2014 will continue this year.

In December, Biocom hosted our 2014 Washington DC Digital Health Advocacy Fly-In, which brought together San Diego companies operating in the digital health space and federal officials to discuss the needs and challenges of this sector. Participants started the day meeting with top management for the Center for Device and Radiologic Health (CDRH) of the FDA, including CDRH Director Jeff Shuren. They then went to Capitol Hill, meeting with key Congressional staff. The event concluded with a meeting at the Office of the National Coordinator for Health IT (ONC), within the Department of Health and Human Services (HHS), with policy director Jodi Daniel.

At the state level, Biocom worked closely with the California Biotechnology Foundation on the program for Speaker Toni Atkins’ and Speaker Pro Tempore Kevin Mullin’s January briefing for new members of the State Assembly. Biocom board chair-elect, Dan Burgess, and longtime San Diego biotech executive, Laura Shawver, educated legislators on the complexity of the industry, as well as its importance to the California economy.

Locally, the San Diego City Council gave final approval in November to a compromise plan for changes to the linkage fee.

Working on behalf of our members, Biocom and our coalition partners were able to negotiate maintaining current fee levels for research and development construction. Other provisions include returning the fee to its 1990 level over the next three years (a 100 percent increase for industries other than R&D) and a strong regulatory reform package.

In December, Biocom held a roundtable discussion with our members and Mayor Kevin Faulconer to discuss the linkage fee, flooding mitigation in Sorrento Valley and economic incentives for businesses. Mayor Faulconer vowed to work with Biocom members to change city processes governing building and permitting. These roundtables will continue in 2015.

Looking into the coming year, the San Diego Congressional delegation is unchanged, and the Orange County delegation gained a long-time friend of the industry, and Biocom, in Congresswoman Mimi Walters. We are excited about continuing to work with this group.

10

Biocom LifeLines Spring 2015

The industry will have to fight against those who would weaken patent protections and the ability to defend intellectual property rights. This was one of the industry’s biggest legislative challenges in 2014, and will continue to be a priority in 2015, as will aggressively advocating for the repeal of the medical device tax.

As of this writing, the House Energy and Commerce Committee has just released a preliminary discussion draft regarding its longawaited 21st Century Cures legislative package. This proposal will likely encounter many twists, turns and changes as it navigates the process, and we encourage you to stay apprised of these via Biocom Biocommunique, our email newsletter, which is distributed every two weeks.

The life sciences industry continues to lead California’s economic recovery as one of the state’s most robust growth areas.

With the recent FDA staff recommendation for approval of a biosimilar, it is important that a proper substitution pathway be established at the state level. Biocom is also watching closely to see if bills attempting to make manufacturers bear the burden of California-specific drug take back and sharps take back programs are re-introduced in this new session of the legislature. The public policy department, and Biocom’s contract lobbyist in Sacramento, continue to monitor legislation that will specifically impact the life science industry in California.

We are prepared for a challenging and exciting policy year.

Please keep an eye on the BCQ for the most current information, and feel free to contact us if you have questions.

Jimmy Jackson is the Senior Vice President of Public Policy for Biocom. He oversees government affairs and public policy for the organization.

GUEST

By Timothy Scott President, Pharmatek Laboratories, Inc.

The Biocom CRO Group: Transforming San Diego’s Life Sciences Outsourcing Industry The story of Akio Morita, founder and former chairman of Sony, is not just a story about developing an iconic brand; it is also a tale of redeveloping an entire country. Started in 1946 in the basement of a department store, Sony grew over the next 50 years to become the number one consumer brand name in the world. But just as important, by insisting on producing the most innovative, highest quality products – made with cutting-edge technology – Morita transformed the Japanese consumer electronics industry, elevating it to equal the highest quality technology companies anywhere.

A similar transformation is occurring in the Southern California life sciences cluster. What was once a handful of small mom and pop contract analytical and testing laboratories has blossomed into a center of pharmaceutical development excellence known around the world.

Biocom launched its CRO Initiative in 2010 to support the growing community of contract research organizations (CROs), which include contract development and manufacturing, clinical research, toxicology and other life science service providers. The CRO Committee began with 22 members in 2010, representing 198 employees. Today, the group consists of 86 members, with more than 1,600 employees in Southern California, providing services for biopharma companies over the entire range of pharmaceutical drug development – from animal studies to human clinical trials.

Since the early 90’s, the San Diego biotech industry has evolved from integrated pharmaceutical and medical device companies discovering new compounds and technologies to companies that deliver compounds and technologies to the clinic using an increasingly diverse host of outsource providers. This evolution has dramatically improved the ability to move new drugs and devices to the clinic. In particular, labor and resource efficiencies have helped companies bring more drugs to patients at lower cost. At the same time, this biopharma evolution has also created a burgeoning industry of life science service providers, which have grown up to serve sponsor-driven science.

As Southern California’s contract research industry has grown, so has the sophistication of its systems and the quality of its programs.

Companies have improved their facilities, engineering controls, quality systems and training programs to become world-class science organizations. The local entrepreneurial attitude has remained, and now it is supported by state-of-the-art programs and facilities.

The growth of San Diego’s CRO industry is based, in large part, on talented people who supply the skills and knowledge to provide development services.

Southern California’s intellectual network connects research institutions, such as UC San Diego, UC Irvine, The Scripps Research Institute, Salk Institute, Sanford-Burnham and many others, to fuel the innovation economy. This network, along with the undergraduate

programs at UC San Diego, UC Irvine, San Diego State and the University of San Diego, provides talented students in biology, chemistry, chemical engineering and computer science to create a dynamic and intelligent workforce. In turn, this workforce provides the talent to discover new technologies, manage their development and provide the services to bring them to fruition.

In addition, the pharmaceutical industry’s workforce reduction over the last five years has created an interesting dynamic between the pharmaceutical and medical device industries and the service providers that support them. More than 250,000 scientists and engineers have been laid off since 2008. This talent loss has led pharmaceutical and device companies to outsource even more of their research and development activities. While some of these employees retired, many took positions with service providers or created their own outsourcing companies to provide services for the same companies that once employed them. This created a massive movement of science and engineering knowledge from one end of the industry to the other. As a result, Biocom CRO members and other life science providers are stocked with talented people.

While it was clear that local CROs, like pharmaceutical and biotechnology companies, have enjoyed taking advantage of Biocom’s membership benefits, the addition of the Biocom CRO Group has enhanced the community. For example, an educational seminar series has trained more than 2,400 Biocom member scientists on clinical trial strategies, medical devices, biomarkers, bioanalytics, formulation development, international collaborations, novel funding strategies, toxicology, managing outsource providers and a host of other topics.

Akio Morita transformed a company, an industry and a country.

The Biocom CRO Group is working to transform San Diego into the best region for outsourced research and development in the industry. This leadership is built on a passion to provide the highest quality services for drug and device development. It is also built by a group of disparate service providers working together towards a common goal: creating a region with best-of-class service in each development area.

The Biocom CRO Group is branding the San Diego region as the place to go for development services, from discovery through development and clinical trial management. Thanks in part to the efforts of the Biocom CRO Group, today, the world comes to San Diego to develop pharmaceutical drugs and technology.

Tim Scott is the President of Pharmatek, the Chair of Biocom’s CRO Committee and serves on Biocom’s Executive Committee and Board of Directors.

Biocom LifeLines Spring 2015

11

GUEST

By Mandy Jackson, West Coast Editor, SCRIP Intelligence

Venture Capital Outlook Optimistic as IPO, M&A Streaks Continue Big pharma companies have billions of dollars at their disposal for acquisitions and partnerships, but so do large biotechnology and specialty pharmaceutical firms, and they are keen competitors for novel drugs and development approaches.

Ernst & Young (EY) said in its recent report Firepower Index and Growth Gap Report 2015: Firepower Fireworks that big pharma invested $90 billion in mergers and acquisitions in 2014, but specialty pharma companies spent $130 billion on M&A. Specialty drug makers’ desires to become larger global players made them willing to outbid big pharma companies, which need to replenish their research and development pipelines to maintain their market status.

Meanwhile, big biotech companies tend to focus more on licensing and partnership deals than on M&A, but EY noted that rapidly increasing sales for companies like Celgene and Biogen Idec are boosting their deal making “firepower.” Those firms are putting their billions of dollars in cash to work in various collaborations, often with early-stage companies that may struggle to raise capital from investors.

of cholestatic liver diseases on track.

“We’re not a company that just takes assets from outside; we keep the people and their expertise,” Shire head of research and development Phil Vickers said.

Celgene, in particular, has a reputation for exploring all kinds of deal structures to find the best fit for all involved. That’s why the maker of the blockbuster multiple myeloma therapy Revlimid (lenalidomide) ranks high in comparison to its peers when it comes to deal making.

Celgene senior vice president of business development George Golumbeski said the company usually prefers licensing deals over acquisitions for earlier-stage drug candidates or platform technologies, because it’s hard to put a concrete value on a preclinical or Phase I program. A licensing deal – even one with an option for Celgene to buy its partner – gives the company a transaction value that makes sense and provides a fair deal value for the collaborator and its investors.

However, Dr Golumbeski said, “If a really good company wanted to be acquired, we would look at it.”

Early-Stage Opportunities The MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, noted that biotech companies raised $6 billion in 2014, the most money since 2007. However, fewer biotechs were able to get venture capital last year: 112 companies raised $2 billion in the fourth quarter compared with 144 biotech firms that raised $1.4 billion during the last quarter of 2013. There were fewer first-time financings as well.

But NVCA also reported recently that in 2014 corporate venture capital reached its highest level since 2000, with $5.4 billion invested by corporate VC funds, including $810 million that pharma and biotech corporate VC funds invested in 98 life science companies.

That means the industry is stepping up its investments in the earliest stages of drug, medical device and diagnostic development.

The Japanese big pharma Astellas launched Astellas Innovation Management (AIM) in late 2013 to work with venture capital firms, biotech startups and academic researchers.

“We’re investing in emerging biology,” AIM vice president Shunichiro Matsumoto said.

Ranking dealmakers Boston Consulting Group found in its 2014 Biopharmaceutical Partnering Survey, which queried 65 executives about licensing deals, that Celgene ranks high in several categories, such as allowing its partners to develop and prosper, flexibility on deal terms, alliance management and allowing collaborators to retain control of joint development programs.

Celgene had the highest average score across all attributes, followed

by Merck, Johnson & Johnson, Roche, Bristol-Myers Squibb and Eli Lilly. AstraZeneca, Novartis and Novo Nordisk also ranked high.

Sophie Kornowski Bonnet, head of Roche partnering, said the company’s business development team works very closely with Pharma Research and Early Development (PRED), the Roche division run by former Sanford-Burnham Medical Research Institute CEO John Reed.

Based on the partnering and PRED divisions’ collaboration, Roche’s business development team is on the hunt for immunotherapy, neurology, infectious disease and diagnostic deals.

“We do creative deals to manage our risk,” Dr. Kornowski Bonnet said.

Dr. Reed noted that Roche is monitoring alternative therapeutic delivery approaches, but the company’s investments in things like gene therapy and RNA-based medicines are limited at the moment.

Flexible dealmaking Large biotech, big pharma and specialty drug makers are discerning about the small and mid-sized biotech companies that they’ll collaborate with or buy. However, they’re also becoming more flexible about deal terms to make transactions work for them and their partners.

Shire acquired Lumena Pharmaceuticals for $260 million in May 2014, but rather than replace all of the company’s employees and install new overseers for ongoing clinical trials, Shire left most of the Lumena team in place in San Diego to keep programs in the treatment

12

Biocom LifeLines Spring 2015

Mandy Jackson is the West Coast Editor of Scrip Intelligence, a biopharma news website, which can be found at www.scripintelligence. com.

TM

NEED ANTIBODIES? GO TO PROSCI. Order Your Custom Antibodies TODAY!

ProSci

Antibodies against diverse

ANTIGENS Characterization and functional

ASSAYS

Send Us Your Sequence, Get the Antibody of Your Interest

Polyclonal Monoclonal Single Domain

ANTIBODIES

Experienced with various formulations of

ADJUVANTS

Wide selection of host species

ANIMALS

Custom Antibody Services • • • • •

>12,000 custom antibody projects completed since 1998 In-house labs and animal facilities in San Diego, CA 150,000 ft2 of animal facilities on 27 acres USDA licensed & NIH/OLAW assured facilities Our custom antibody services are widely cited in scientific literature

prosci-inc.com | info@prosci-inc.com | 858.513.2638 © 2015 ProSci Incorporated. All rights reserved.

Antibody development and production expertise is the foundation on which ProSci is built. Since 1998, ProSci has conducted HIV neutralizing antibody research and has been a leading provider of custom antibody services and catalog antibodies worldwide.

Need Antibodies? Go to ProSci.

GUEST

By Ed Miseta, Executive Editor, Life Science Leader Magazine

A forum on the business of outsourcing is coming to San Diego The inaugural Outsourced Pharma West Conference and Exhibition, held last November in San Francisco, hosted more than 200 professionals, including 40 panelists and 45 sponsors.

Participants represented executive leadership from early stage through large pharm and biopharm companies, as well as suppliers and investment firms.

The format fostered an open dialogue on the business of outsourcing, during which attendees engaged in a dynamic backand-forth on challenges and opportunities. The conversation was unscripted, direct and honest. What follows is a window into two of the program’s lively sessions and a look forward to the 2015 conference in San Diego.

Challenging the “one-stop shop” trend Panel: Matching a Vendor to Your Stage of Development Panelists: Firelli Alonso-Caplen, Pfizer; Jon Crate, FAI Testing Services; David Enloe, Althea; Joe Guiles, Medivation; Bob Munday, CMC Biologics; Patrick Murphy, Versartis; John Ross, Metrics An attendee requested advice for small firms that are restricted to working with a single supplier due to resource limitations.

Murphy’s experience with a small company differed. “I’m not going to be exclusive. I’m going to go to whoever has the ability at that point in time, the interest to accept the risk of a small company and somebody that I can trust.” Additional commentary also countered. “[Small companies] really can’t afford for things to go wrong. You can send the same sample to multiple labs, and you can get CMOs to compete for your work. Once they compete for that work, you’ve got a feel for whether they can actually do it. If one starts letting down, you’ve already got the other one prequalified.”

The conversation naturally shifted to the trending “one-stop shop” model. Enloe pushed back, commenting, “My observation is that CMOs are a lot more willing to say what they’re good at and what they’re not good at right now. A rising tide lifts all ships, and I don’t see, other than outside of a very few technical areas, where there’s this incredible premium for it to be all one place.” Murphy agreed, “I’ve never actually seen a one-stop shop. I assume that that’s a company that can do everything. I’ve never found one.”

Understanding how venture capitalists assess your presentation Panel: Finding Capital That Matches Your Goals Panelists: Chris Achar, Genzum Life Sciences; Tiba Aynechi, Novo

14

Biocom LifeLines Spring 2015

Ventures; Kevin Judice, entrepreneur; Julie Papanek, Canaan Partners; Jaisim Shah, Semnur Pharmaceuticals; Mahendra Shah, Vivo Capital; Wayne Koberstein, Life Science Leader Discussion focused on preparing entrepreneurs to secure funding.

Jaisim Shah advised, “There are several areas that you must be prepared to address. One is a clear understanding of the unmet need you are trying to address. Not just the scientific or medical need, but also the business need. Having a clear understanding of your development path and what the FDA expectations may be for developing your product is key.” Papanek issued a warning, explaining, “I have seen some capitalization tables come over with 150 names on them. I would worry that some of those people are not qualified investors and that at some point we will have to figure out how to get their capital out of the company. This is why you should think hard about whose money you are taking.”

Save the date for Outsourced Pharma West in San Diego Outsourced Pharma West Conference and Exhibition August 25-26, 2015, Hyatt Regency La Jolla Co-produced by Life Science Leader magazine and Biocom outsourcedpharmawest.com Outsourced Pharma West is privileged to come to Southern California in 2015 with the generous support of Biocom. As partners, Life Science Leader and Biocom can further advance the conference’s mission to address key business decisions involved in maintaining relationships for development and manufacturing.

This growth is possible only with active participation from Biocom members and the region’s wider community — the players driving Southern California’s leading role in the global development pipeline. We invite you to come together this August for what promises to be another insightful experience.

Biocom and Life Science Leader magazine will co-produce Outsourced Pharma West San Diego in 2015.

Ed Miseta is the Executive Editor for the Life Science Leader magazine

TRANSFORMING REAL ESTATE INTO REAL

ADVANTAGE For every client, advantage is delivering the broadest, deepest reach and resources any real estate company offers.

Transforming property into prosperity, square feet into strong portfolios, scale into global strength. All in service of exceptional outcomes that build real business advantage. Let us put our actionable perspectives, global reach and powerful connections to work for your business.

cbre.com/sandiego-occupier @cbresandiego

Build on Advantage

BIOCOM INSTITUTE

By Liisa Bozinovic, Executive Director, Biocom Institute

What are We Doing Now? The Biocom Institute has a unique role: supporting the existing life science workforce and the business leaders charged with hiring, training and retaining them and nurturing the future workforce all the way down to pre-K. For Biocom members, the Institute provides a career center with discounted job postings, an internship program toolkit and discounted professional development courses in leadership, biotech and med device basics and presentation skills. In 2015, we are launching a free salary survey for participating Biocom members.

As for supporting the community and the future of the life sciences industry, our main programs for 2015 include: San Diego Festival of Science & Engineering The Festival has been a great addition to the Biocom Institute since coming to us from UCSD in 2013. We couldn’t be happier about all the community exposure our industry gets through the Festival. We especially enjoy the kids’ excited faces on Expo Day and the many other events throughout the community in the preceding week. Please check out the separate article on the Festival in this edition of Lifelines for a glimpse of all the fun activities.

Veteran Career Mentoring and Technical Training Piloted in the summer of 2014, the first of three four-month sessions of our Veteran Career Mentoring program officially kicked off on January 15 with a professionally-led, goal-setting session.

The program includes one-on-one mentoring from veterans currently working in executive and management positions in business development, marketing, human resources, science and other areas. In addition, with the opportunity to attend relevant, industry-specific events, veterans are taught how to network. Additional workshops help them improve their careerreadiness skills. In development this year, Fatigues to Lab Coats trains veterans to become certified bio technicians, using live, publishable research projects.

Teacher Fellows In 2015 this program is expanding to provide STEM educators even more access to life sciences companies. The 30 fellows in the program attend an industry mixer, during which teachers and education outreach and community relations managers will network and begin forming relationships, improving the link between classrooms and industry. Teachers will participate in an

16

Biocom LifeLines Spring 2015

industry job shadow in the summer, during which they spend “a day in the life” of a science, engineering or computer professional.

Teachers will again attend an international medical device sector conference being held in San Diego. The AdvaMed conference is expected to draw about 2,500 industry professionals over the threeday conference in October. Lastly, the program includes a best practices seminar, during which teachers will share after-school club and classroom project ideas, successes and challenges.

STEM Voice Video Competition Last year, we launched the competition nationally with a heavy local emphasis and more than 65 percent of the entries, including the first runner up, were from the San Diego region. In 2015, the contest design remains the same. Students in grades 5 -12 create a one-minute video on STEM and compete for cash prizes.

Kids will compete at regional levels before a national winner is chosen. We will be recruiting judges and expect to see even more creative videos this year, as well as maintaining a high level of local participation. It’s debatable who has more fun: the kids making the videos or the judges watching them. Last year brought all kinds of creative STEM fun – superheroes, surfing, Legos, mad scientists and more.

As a separate 501(c)3, at the Biocom Institute, we rely heavily on partnerships and volunteer support for all that we do. We encourage you to contact us to find out how you can get involved and help make the next 20 years even better than the last.

Liisa Bozinovic is the Executive Director of the Biocom Institute and also heads Biocom’s HR Initiative.

SCIENCE FESTIVAL

By Sara Pagano, Managing Director, SD Festival of Science & Engineering

Come Ignite Your Love for STEM they gather data and conduct experiments during criminal From Saturday, March 14 through Saturday, March 21, festival investigations. Officers and laboratory technicians will explain how week events and EXPO Day will engage the entire community of scientific principles are used daily to solve crimes and reconstruct San Diego County. In 2015, we anticipate more than 65,000 traffic collisions. kids, parents, scientists, educators and community members will Looking for a VIP Experience? Take a behind-the-scenes lab tour participate in festival week activities. Another 24,000 will attend at Scripps Institution of Oceanography. View the Hydraulics Lab, EXPO Day at Petco Park, where more than 130 local businesses, featuring a wind/wave channel, a wave flow channel, a deep tank corporations, and organizations will provide interactive, hands-on and pressure testing. Learn about the Coastal Data Information science, technology, engineering and math exhibits and activities Program (CDIP), which specializes in wave measurement, swell for budding K-12 science lovers. modeling and forecasting and analyzing coastal environment data.

Stretching into our seventh year, the San Diego Festival of Science See the CDIP buoys and learn from & Engineering inspires students the team how they are built and to become tomorrow’s science, “Through programs like the San Diego Festival deployed around the world’s oceans. technology, engineering, and math Embrace your artistic side (STEM) innovators. San Diego is a of Science & Engineering we can by viewing the honorees of our hot bed for scientific innovation, inspire tomorrow’s leaders to pursue educational inaugural STEM Design contest offering a uniquely collaborative opportunities that will further San Diego’s legacy of and participating in a live painting spirit, high concentration of worldinnovation , grow our economy, and ultimately, experience inside Petco Park. class research institutions and a create products that change the world.” - Jay Be a part of the “Second Hour strong foundation for new company Flatley CEO, Illumina of Code” and help the Festival get creation and development.

PRESENTED BY into the Guinness Book of World Presented by Illumina, the Records, by participating in the festival is a catalyst to transfer largest K-12 coding event ever that knowledge and collaboration, attempted in one place! This event showing students and their parents will be hosted by Microsoft and will take place inside the stadium how science, technology, engineering and math translates into with a live lesson from our dugout stage! In addition, Microsoft careers and further fuels our local economy. Science is all around will hold their special experience lounge in the Omni Premier Club us and is the foundation for much of modern life. inside of PETCO. Be sure to head over to www.lovestemsd.org to see our full A snapshot of the 2015 program… events listing and plan your itinerary for the week. Many of the San Diego State University (SDSU) will host the first-ever STEM activities are free and can accommodate school groups, scout College Connections Fair. The event will feature a college expo, troops students and families. EXPO Day, on March 21 at PETCO with representatives from 40 to 50 colleges and universities from Park, is FREE and open to the public. across the U.S., to answer questions about their STEM degree The Festival believes that encouraging young students and programs. Students will also be able to learn more about college families to engage in STEM is a stepping stone to strengthen our life and future STEM careers at several Q&A panel discussions. communities and foster the next generation of trendsetters for San Heard of cyanotyping? Do you know anything about it? You Diego. Please join us, and embrace the learning and fun, March will after visiting the High Tech High International (high school 14 - 21, 2015. level Bright Idea Society winners) booth on EXPO Day. By mixing emulsions from raw chemicals and placing various objects and photos on photosensitive paper, visitors will create their own Sara Pagano is the Managing Director of the cyanotype pictures to take home.

San Diego Festival of Science & Engineering How about CSI So Cal? Tour the Escondido Police Department, where the Crime Lab and Traffic Division will showcase how

Biocom LifeLines Spring 2015

17

PURCHASING GROUP

By Rick Fultz, Managing Director, Biocom Purchasing Group

Biocom Your Move Biocom is the largest regional life science association in the world with more than 650 member companies, most residing right here in San Diego. As a member-driven organization, we work day and night to bring you value – strategically, financially and operationally – through a diverse range of programs and initiatives.

In Biocom’s 20 years of serving the San Diego life sciences community, the Biocom Purchasing Group has been an evolving partner, discovering the science of savings for our members. We are an entity geared toward leveraging our members’ hundreds of millions in collective purchasing power to obtain discounts from vendors in five fundamental categories: data and communications, facilities & operations, HR and finance, lab supplies and travel.

In 2014 alone, we saved our members more than $90 million.

One area where Biocom has made a tremendous impact on the bottom line is our members’ facility and daily operational needs.

Our members move, expand, downsize, build out and change their footprints quite frequently here in Southern California. Over the past two decades, Biocom has been an instrumental partner in these efforts.

As we head into Biocom’s 20th year, our strategic goal is to play a stronger role developing our life sciences community. That means building on our members’ current footprints and ensuring pharma and biotech companies see the value of continuing to do business here in San Diego.

This is how our new initiative, Biocom Your Move, was formed.

Your Blueprint for Success We understand the many factors that need to be considered during a corporate move, expansion or relocation. We have moved twice in the last twelve months, and we strongly believe that the most crucial component to a successful move is finding a comprehensive moving team that offers a wide variety of resources and dedicated service partners who specialize in meeting your needs.

Whether you are planning a move, expansion or facility reconfiguration, Biocom can help you save valuable time and money through our portfolio of vetted suppliers and an expanded network of consultants who specialize in meeting your unique life sciences needs. From decommissioning existing labs, starting up news ones, designing innovative workspaces, sourcing furniture and establishing IT systems and the technologies that will power them, Biocom is a partner you can count on for your next successful move.

18

Biocom LifeLines Spring 2015

Your One-Stop Shop Our endorsed suppliers have gone through rigorous RFPs and were chosen as best-in-class by an ad hoc committee of key industry Biocom members. Fourteen of these suppliers offer significant discounts to Biocom members, as well as specific terms and conditions and exceptional service commitments to streamline a corporate move.

These suppliers are committed to working with you and your internal task force to devise a moving plan that eliminates stress, minimizes downtime and disruptions and allows for a seamless office transition. They even have experience working with each other since joining our portfolio and have worked out a system to streamline projects and communication.

The Biocom Your Move initiative is an extension of an already solid framework within the Biocom Purchasing Group portfolio of savings. Let us equip you with a great set of tools to provide true value and savings for your company.

As you begin to focus on the best way to transition to your new environment, remember to secure an award-winning corporate relocation team to manage your move. Contact Biocom’s Member Benefits Manager, George Bonaros, at 858.455.0300 x107 to get started on building your team today.

Rick Fultz oversees membership and sponsorship efforts, business development opportunities, and the Biocom Purchasing Group.

PREMIUM MEMBER SPOTLIGHTS PREMIUM MEMBERS AbbVie Airgas* Alexandria Real Estate Equities Althea Arena Pharmaceuticals Bayer Healthcare Biomed Realty Trust Biospace BP Biofuels California Manufacturing Technology Consulting Canale Communications Celgene City National Bank COI Pharmaceuticals Conatus Pharmaceuticals Cooley LLP Deloitte DLA Piper Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic J-Labs Jones Day KPBS Latham & Watkins Mallinckrodt Plc Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo NuVasive Office Depot* Patheon Pfizer Praxair Prometheus Laboratories PwC Thermo Fisher Scientific Unisource Solutions VWR International Wilson Sonsini Goodrich & Rosati * New Members from October 2014 to January 2015

20

Biocom LifeLines Spring 2015

www.ey.com Name: Jennifer L. Brown Job title: Executive Director, Assurance and Advisory Business Services – Life Sciences Favorite movie: The Blind Side, Sweet Home Alabama Favorite TV show: Castle Favorite restaurant or meal: Steak and Lobster Favorite city: San Diego (of course! Since I am a native) Favorite actor/actress: Sandra Bullock Favorite thing to do on the weekends: Go to the movies with the family, enjoy all San Diego has to offer What CD can we find in your car: Blake Shelton or The Band Perry Favorite hobby: Photography/Scrapbooking Favorite website: Shutterfly (for sharing pictures and managing all my daughter’s Girl Scout Troop activities where I am the Troop Leader – Need any Thin Mints?)

Favorite spot in Southern California: Torrey Pines State Park First job: Roundtable Pizza (High School) making pizzas!

Favorite part of your job: Helping early stage biotech companies succeed in raising capital If you could have another career, what would it be: Teacher Why did you start working in your industry: Working in public accounting is a good way to learn about different types of business and industries, how successful companies operate and the pitfalls to avoid in creating business policies and practices when starting a business. With this background and experience you can move on in many different directions. I ended up going into industry and then returning to public accounting when I joined EY 20 years ago and made it my career. I enjoy helping my emerging biotech clients strengthen the financial aspects of their businesses to help them succeed in pursuing their research and development goals.

www.wsgr.com Your Name: Miranda Biven Job title: Partner Favorite movie: Charade (with Carey Grant and Audrey Hepburn) Favorite book: Lie Down in Darkness by William Styron, but Sheila, The First Hippo on the Moon by David Walliams is a close second Favorite quote: “Freedom is the freedom to think otherwise” (Rosa Luxemburg) Favorite TV show: MI5 (a British BBC series which is not showing anymore), or for something current, Orphan Black Favorite restaurant or meal: It’s still almost anything my mother cooks Favorite city: Sydney Favorite actor/actress: Helen Mirren Favorite thing to do on the weekends: Going to the beach with my family – it’s the best way to wear out two small boys What CD can we find in your car: The Wiggles Favorite hobby: Reading Favorite website: Sydney Morning Herald (www.smh.com.au) for some news from home Favorite spot in Southern California: My house in Solana Beach when it’s not under construction First job: A waitress - it only lasted 2 hours and I didn’t get paid. Does that count?

Favorite part of your job: Meeting and working with interesting and entrepreneurial people If you could have another career, what would it be: A doctor or, in my less practical moments, a staff writer for the The New Yorker Why did you start working in your industry: Surprisingly, there was not a huge demand for people with a thesis in 1920s Jazz history. I was also interested in the intersection between law and new scientific developments (at the time, it was the early days of embryonic stem cell research, the human genome project and cloning) so representing life sciences companies was a good way to combine those interests.

PREMIUM MEMBER SPOTLIGHTS www.lw.com

www.pfizer.com Name: Carolyn Lemm Job title: Director of Business Operations for the Late Phase Strategy, Development, Submission, and Lifecycle Management Group

Name: Matthew Grant Job title: Associate

Favorite movie: Rear Window Favorite book: Too many – love crime and suspense novels Favorite quote: “You can’t use up creativity. The more you use, the more you have.” –Maya Angelou Favorite TV show: Modern Family Favorite restaurant or meal: Italian, Italian, Italian Favorite city: Sydney, Australia Favorite actor/actress: Harry Connick, Jr. – an amazing actor and musical talent Favorite thing to do on the weekends: Spending time with my children doing just about anything What CD can we find in your car: Dave Matthews Band (Under the Table and Dreaming) Favorite hobby: Cooking and attending live theater, music, or sporting events Favorite website: Pinterest Favorite spot in Southern California: My home First job: Dance Instructor for children Favorite part of your job: Helping others achieve success and solutions If you could have another career, what would it be: A Travel Writer or Arts Critic Why did you start working in your industry: Destiny… My background is Accounting & Finance and I never excelled in science courses, yet I married a scientist and now work in the healthcare industry. I am so thankful to be part of Pfizer working with talented colleagues everyday bringing medicines and therapies to patients.

Why did you start working in your industry: Unbelievably large amount of fun.

Make Your Mark

Favorite movie: Life is Beautiful (1997) Favorite book: Biographies, generally Favorite quote: “True happiness is not made in getting something. True happiness is becoming something.” - Marvin J. Ashton Favorite TV show: College football Favorite restaurant or meal: Steak and potatoes Favorite city: Washington, D.C. Favorite actor/actress: Denzel Washington Favorite thing to do on the weekends: Any new adventure with my wife and kids What CD can we find in your car: “Frozen” soundtrack right now (thanks to my daughters) Favorite hobby: Snowmobiling Favorite website: ESPN.com Favorite spot in Southern California: Torrey Pines bluffs First job: Janitor at a sheet metal manufacturing plant when I was 14 Favorite part of your job: Finding creative solutions to clients’ problems If you could have another career, what would it be: High school teacher Why did you start working in your industry: I like working with a variety of clients, most of whom are successfully developing and/or marketing really fascinating products and services that improve a lot of peoples’ lives

in

BiotechnologY

Professional Science Master’s The Professional Science Master’s in Biotechnology from CSUSM is a degree that leads to jobs with graduates reporting a 97% employment rate at time of graduation. This innovative degree incorporates advanced biotechnology coursework and laboratory training with MBA-level business courses. The part-time evening program accommodates the needs of working professionals. Our graduates are well-prepared for successful careers and advancement in the life science industry.

For more information contact us at www.csusm.edu/el/psmlifelines

APPLY TODAY!

BOARD OF DIRECTORS BOARD OFFICERS AND EXECUTIVE COMMITTEE: CHAIR: Theodore Schroeder* VICE CHAIR: Carin Canale-Theakston, Canale Communications* CHAIR ELECT: Daniel Burgess* VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper* VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young* VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield* CHAIR EMERITUS: Magda Marquet, Ph.D., Althea (A member of the Ajinomoto Group)* PRESIDENT & CEO: Joe Panetta, Biocom* Vincent Anido, Ph.D., Aerie Pharmaceuticals Steven Bartz, Ph.D., Merck & Company Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo Michael Boyd, AbbVie Michael Brown, Stradling Yocca Carlson & Rauth Terrance J. Bruggeman John M. Dunn Stephen Ferruolo, J.D., Ph.D., USD School of Law* M. Wainwright Fishburn, Jr., Cooley LLP* Don Fitzgerald, Genentech Jack Florio Gregory Fond, Sanofi Global R&D Gregory Frost, Intrexon Corp.

Carol Gallagher Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Jason Hannon, NuVasive Richard Heyman, Ph.D. Jim Hinrichs Elliot Hirshman, Ph.D., San Diego State University Matthew Hudes, Deloitte LLP Guy J. Iannuzzi, Mentus Gerald Joyce, M.D., Ph.D., Genomics Institute of the Novartis Research Foundation David Kabakoff, Ph.D., Sofinnova Ventures Steve Kaldor, Ph.D., Quanticel Katherine Kantardjieff, Ph.D., California State University San Marcos Paul Laikind, Ph.D., ViaCyte Jacob Levin, Ph.D., UC Irvine James Levine, Sapphire Energy* Jack Lief, Arena Pharmaceuticals, Inc.* John Lister, Dexcom

Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.* William Molloie, PwC Tracy Murphy, Biomed Realty Trust Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.* Perry Nisen, M.D., Ph.D., Sanford-Burnham Medical Research Institute Brian O’Callaghan Kenneth Polin, Jones Day Trindl Reeves, Barney & Barney LLC* Gregory Reyes, M.D., Ph.D., Celgene Dan Ryan, Alexandria Real Estate Equities Camille Saltman, Malama Composites, Inc. James Schaeffer, Ph.D., Calibr* Christophe Schilling, Ph.D., Genomatica, Inc.* Timothy Scott, Pharmatek* Bhasker Shetty, Ph.D., Pfizer La Jolla Larry Stambaugh, Kalos Therapeutics* Mark Stevenson, Thermo Fisher Scientific* Tsuneo Takahashi, NF Corporation Scott N. Wolfe, Latham & Watkins LIFE DIRECTOR: Kennon W. Baldwin, Ferguson Pape Baldwin Architects* David Hale, Hale BioPharma Ventures* Tina Nova, Ph.D., Ilumina Biocom Board Members-Ex-Officio: Sandra Brown, Ph.D., UCSD Mark Cafferty, San Diego Regional Economic Development Corporation Constance Carroll, Ph.D., San Diego Community College District Scott Lippman, MD, Moores Cancer Center, UCSD Greg McKee, CONNECT Peter Preuss, The Preuss Foundation Jerry Sanders, San Diego Regional Chamber of Commerce David Webb, Ph.D., Scripps Research Institute *Executive Committee Member

COMMITTEE LEADERSHIP Biocom Institute Board Committee* Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc. Capital Development Committee* Carin Canale-Theakston, Canale Communications David Kabakoff, Ph.D., Sofinnova Ventures CRO Committee Timothy Scott, Pharmatek Environmental, Health and Safety Committee Cliff Hanna Dan Shiel, Pfizer La Jolla Facilities Committee Andy Darragh, Ferguson Pape Baldwin Architects Brent D. Jacobs, Cushman & Wakefield

22

Biocom LifeLines Spring 2015

FDA Committee Magda Marquet, Ph.D.,Althea (A member of the Ajinomoto Group) Michele Yelmene, Pharmalink Consulting Intellectual Property and Patent Law Committee Daniel Hart, Knobbe Martens Olson & Bear LLP Michael Mueller, Conatus Pharmaceuticals International Committee Kenneth Polin, Jones Day Legislative Committee Richard Ledford April Grant, Sunovion Pharmaceuticals Medical Device Committee Mike Oliver, Spectra Science

Joleen Schultz, Rady School of Management, UCSD Digital Health Committee Kira Jenkins, Biocom Public Policy Oversight Committee* Larry Stambaugh, Kalos Therapeutics Paul Laikind, ViaCyte Purchasing Board Committee* Jack Lief, Arena Pharmaceuticals, Inc. Scholarship Committee Bente Hansen, BenteHansen and Associates Veterans Committee Josh Vocovic *Board Level Committees

BIOCOM MEMBERSHIP PREMIUM

California Manufacturing Technology Consulting Canale Communications Celgene City National Bank COI Pharmaceuticals Conatus Pharmaceuticals Cooley LLP Deloitte DLA Piper

Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic J-Labs Jones Day

KPBS Latham & Watkins Mallinckrodt Plc Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo NuVasive Office Depot*

Patheon Pfizer Praxair Prometheus Laboratories PwC Thermo Fisher Scientific Unisource Solutions VWR International Wilson Sonsini Goodrich & Rosati

BIOTECHNOLOGY

Cell Applications Celladon Cellana Center for Aquaculture Technologies Chubu Technology Licensing Office Cibus Cidara Therapeutics Coda Therapeutics Conju-Probe Contract Biotics Crinetics Pharmaceuticals Custopharm Cypher Genomics Dart Neuroscience Definiens Diomics Corporation* DNAtrix DSM Food Specialties E&B Technologies eFFECTOR Therapeutics Elcelyx Therapeutics Electronic BioSciences eMolecules Epeius Biotechnologies Equitech Bio Eton Bioscience Fabrus Fate Therapeutics Formex Genelux Corporation Genentech Genlantis Genoa Pharmaceuticals Genomatica Genovo Corporation GenSignia Life Sciences GigaGen* GlaxoSmithKline Global Medical & Research Technologies Guangdong Consun Pharmaceutical Company GWR Instruments Halozyme Therapeutics Histogen Human Longevity Huya Bioscience International IDEXX BioResearch Illumina

Imprimis Pharmaceuticals Inception Sciences Inhibrx InnoPep Innovative Cell Technologies Inovio Pharmaceuticals Integrated DNA Technologies Intercept Pharmaceuticals International Stem Cell Intrepid Therapeutics Intrexon Corporation Intrinsic LifeSciences Invetech InvivoGen IRBCo. ISIS Pharmaceuticals J-Oil Mills JSR Micro Kalos Therapeutics* Kalyra Pharmaceuticals Koltan Pharmaceuticals Kura Oncology* Kyowa Hakko Kirin California La Jolla Biologics La Jolla Pharmaceutical Company Ligand Pharmaceuticals Lpath Lumena Pharmaceuticals MabVax Therapeutics Malama Composites Mast Therapeutics MEI Pharma Meritage Pharma Miltenyi Biotech Mirati Therapeutics Monsanto MultiVir Nautilus Environmental Neothetics NeuroGenetic Pharmaceuticals NF Techno Commerce Nitto Denko Technical Novartis Pharmaceuticals Novo Nordisk Nucelis Ocera Therapeutics Ohr Pharmaceuticals Optimum Therapeutics Orexigen Therapeutics

OrPro Therapeutics Otonomy Pacira Pharmaceuticals Panmira Pharmaceuticals Patara Pharma* Pathway Genomics PersImmune* Pfenex PharmAkea Polaris Group Polynoma PolyPeptide Group Predictive Biology PrimaPharm PrimeGen Biotech Primordial Genetics Prognosys Biosciences ProSci QED Bioscience Qingdao Ming Yaotang Medical Technology Qingdao Newsummit New Drug Public Service R&D Platform Quanticel Pharmaceuticals Receptos Regulus Therapeutics REKA Health Rempex Pharmaceuticals Renova Therapeutics Ribomed Biotechnologies Ridgeline Engineering Roche Applied Science Rohto Pharmaceutical RQX Pharmaceuticals RuiYi Sapphire Energy Samumed Samsara Sciences* Sanofi Sciencescape Scripps Laboratories Senju USA Senomyx SentĂŠ Seragon Pharmaceuticals SG Biofuels Silicon Biosystems* Sirenas Marine Discovery Solstice Biologics

SomaLogic Sophiris Bio Sorrento Therapeutics SOVA Pharmaceuticals Stemedica Cell Technologies Sunovion Pharmaceuticals SynteractHCR Synthetic Genomics Takeda Pharmaceuticals U.S.A. Tanabe Research Laboratories TEGA Therapeutics Tenova Pharmaceuticals Thesan Pharmaceuticals Tocagen Tonbo Biosciences TP Therapeutics Tracon Pharmaceuticals Tragara Pharmaceuticals Triphase Accelerator Trius Therapeutics UCB US Specialty Labs Vala Sciences Vantari Genetics Vaxiion Therapeutics Verdezyne Vertex Pharmaceuticals Vet-Stem ViaCyte Vical Viking Therapeutics Visionary Pharmaceuticals Vital Therapies Wellspring Biosciences Wildcat Discovery Technologies World Fusion US* Xencor* Xycrobe Therapeutics Zogenix

AbbVie Airgas* Alexandria Real Estate Equities Althea Arena Pharmaceuticals Bayer Healthcare Biomed Realty Trust Biospace BP Biofuels

Abcore* Abgent Abide Therapeutics Abwiz Bio ACADIA Pharmaceuticals ActivX Biosciences Advanced BioMatrix Advanced Targeting Systems Aerie Pharmaceuticals Afraxis Agena Bioscience AM Chemicals AMBRX Ambryx Biotechnology Amgen Amicrobe Amplyx Pharmaceuticals AnaptysBio AndroScience Ansun Biopharma Apricus Biosciences Arcturus Therapeutics Ardea Biosciences Arrayomics Astellas Pharma aTyr Pharma Auspex Pharmaceuticals Avantgen Avelas Avidity NanoMedicines Aviva Biosciences Bachem Americas BASF BioLegend Biomatrica Biomyx BioNano Genomics Bionomics Bio Options BioSpyder Technologies BioWa Boehringer-Ingelheim Curtana Pharmaceuticals CalciMedica CannaVest Corporation CARBOGEN AMCIS Cebix

* New Members from October 2014 to January 2015

Biocom LifeLines Spring 2015

23

BIOCOM MEMBERSHIP CRO/CMO

Behavioral Pharma Bend Research BioAgilytix Labs BioAtla Bioserv Corporation BTS Research CalChem Synthesis Cassia Cato Research Charles River Laboratories ChemDiv Combi-Blocks Concortis Biosystems Cytelligen Davos Chemical DD Studio Denovo Biomarkers Drug Delivery Experts

Epistem eStudySite Exon BioSystems Expertise Engineering Explora BioLabs GENEWIZ GRAM Laboratories Hamari Chemical San Diego Research Center HD Biosciences* Huntingdon Life Sciences IMS Health* Integrium Clinical Research Interplex Sunbelt inVentive Health Clinical IriSys JadeBio LCMS Solutions

Mediconomics MicroConstants Molecular Response MPI Research My Chem LLC* Neuroservice Neuro-Sys OOxesis Biotech PacificGMP PharPoint Research Pharmatek Laboratories Profil Institute For Clinical Research PSI CRO Puracyp Quadrants Scientific RetroVirox Reveal Biosciences Rho

Robarts Clinical Trials Roowin SAFC Pharma Sherpa Clinical Packaging Spaulding Clinical Research Starfish Medical Therapeutics, Inc. Tioga Research Toxikon Triligent International Ultimate Labs Verum.us VIRAPUR Wax-It Histology Services WuXi AppTec Zensun USA Zyagen

MEDIC AL DEVICE & DIAGNOSTIC

Celula Cliniqa Corporation ClinMet Compellon CRISI Medical Systems Critical Diagnostics Cure Care CTK Biotech CVAC Systems Cytori Therapeutics DermTech International DexCom Diagnostic Consulting Network Dorsa Vi USA Ellipse Technologies Emerge Diagnostics Endologix Enigma Diagnostics Entra Health Systems Epic Sciences Epitope Diagnostics

Fallbrook Engineering FemCap Fortimedix USA Freedom Meditech GenWay Biotech Glaukos Corporation Glysens Hitachi Chemical Research Center Hygeia Medical Ichor Medical Systems Ignyta ImpediMed ImThera Medical Inari Medical* Inceptus Medical INOVA Diagnostics Interpreta Interventional Spine InVision Biomedical Group Invivoscribe Technologies Ionian Technologies

Ivantis Ivera Medical KFx Medical Liferiver MARDX Diagnostics Medipacs* Micell Technologies Millennium Health Nano Imaging Services Nanomedical Diagnostics NuFACE Omniome OncoSec Medical Organovo Parallel 6* Pediatric Bioscience* Prometheus Laboratories Qualigen Quidel Quinn Medical ReShape Medical

REVA Medical ReVision Optics Ridge Diagnostics Roka Bioscience Sequenom Sequent Medical* Shire Sienna Labs Sirigen Sonendo SpectraScience Suneva Medical Tandem Diabetes Targeson TherOx Tristan Technologies Trovagene Uptake Medical Yulex

NON-PROFIT

ISM San Diego J. Craig Venter Institute Kaiser Permanente KOTRA - Los Angeles La Jolla Bioengineering Institute La Jolla Institute for Allergy & Immunology Lawrence Family Jewish Community Center Los Angeles Biomedical Research Institute Medicon Valley Alliance MiraCosta College Biotech Program Mt. San Jacinto College PhRMA Point Loma Nazarene University Quebec Government Rady School Of Management, UCSD Salk Institute For Biological Studies

San Diego Biomedical Research Institute San Diego Blood Bank San Diego Clinical and Translational Research Institute, UCSD San Diego Community College District San Diego Employers Association San Diego Natural History Museum San Diego Regional Chamber of Commerce San Diego Regional Economic Development Corp.

San Diego Supercomputer Center (UCSD) San Diego Workforce Partnership Sanford-Burnham Medical Research Institute Scottish Development International Scripps Health

Scripps Research Institute Swedish American Chamber Of Commerce San Diego The BioIndustry Association The Lowy Medical Research Institute (LMRI) Torrey Pines Institute for Molecular Studies UC San Diego Extension UCI’s Office of Research UCSD, Department of Bioengineering UCSD, Health Systems- Center for Occupational & Environmental Medicine UCSD, Office of Advancement UCSD School of Medicine UCSD, Technology Transfer Office UK Trade & Investment University of San Diego

INDIVIDUAL

Abbiotec Absorption Systems Accelagen Accugent Laboratories Acurian Advantar Laboratories Agility Clinical Alliance Protein Laboratories Ambit Biosciences American Peptide Company AnaBios Animantis* Annova Chem ARIANNE Atheln Beaufort CRO

Acon Laboratories Aethlon Medical Alphatec Spine AltheaDx Applied Proteomics Astute Medical Axonics Modulation Technologies* Banyan Biomarkers BeneChill Biocept BioDx Biological Dynamics Biomerica bioTheranostics Breathe Technologies Bruin Biometrics Cell Idx CeloNova BioSciences

American Cancer Society, Border Sierra Region Battelle CA Institute for Regenerative Medicine Calibr California Baptist University, College of Engineering California Medical Innovations Institute California State University, San Marcos City Of Murietta CONNECT Consulate Of Canada CSU,CSUPERB Program Human BioMolecular Research Institute Institute of Engineering in Medicine

24

Biocom LifeLines Spring 2015

Antoinette Azevedo Bernard King Carol Gallagher Donna Janson Elliot Parks Gary Friedman John Dunn John Kavanagh Julie Ames Peter Preuss Richard Ledford

KEY PROVIDER Barney & Barney Cushman & Wakefield Oracle Health Sciences Qualcomm San Diego Gas & Electric

PROVIDER

2Connect Accelrys ADVI AER Travel AIS Data Centers Alexander’s Mobility Services AMN Healthcare Assay Depot Austin Commercial Bank of America* Beckloff Associates Bench International Bente Hansen & Associates Berkshire Hathaway Home Services Bionest Partners BioSurplus Biotech Primer Biotech Vending BioTix Blue Sky Broadcast Bootstrap Incubation

Caliber Associates California Commercial Security Cambridge Research Biochemicals Canteen Vending Services CBRE China Business Partners Chubb Group of Insurance Companies Clinigen Healthcare Controlled Contamination Services Corning Covisint Corporation Cox Business CSCI Cymer Domain Associates EBD Group Elsevier Enterey EquipNet Euretos Exp U.S. Services Ferguson Pape Baldwin Architects Fisher & Phillips Forward Ventures Fragomen, Del Rey, Bernsen & Loewy French Biobeach Frequentz Gable PR Gamxing* Gensler G/M Business Interiors

Grande Colonial Hartl Team- Private Banking & Investment Group- Merrill Lynch Haworth HCP Life Science Estates H.G. Fenton Company Hyatt Regency La Jolla at Aventine IBM Life Sciences Innovative Lease Services J.T. MacMillan Photography Jackson & Blanc HVAC Contractors Jones Lang LaSalle Kilroy Realty Knobbe, Martens, Olson & Bear Leadership Edge Legacy Partners Commercial Lonza AG* Managed Laboratory Services* Managed Solution Mayer Hoffman McCann McKenna Long & Aldridge Medidata Solutions Medline Industries Mehlman Barnes Mercury Fund Morgan, Lewis & Bockius Morrison & Foerster Occupational Services Orion International Patent Office Outlier Solutions Oxford Finance

Pharmalink Consulting PR Newswire Prevost Construction Procopio, Cory, Hargreaves & Savitch Project Management Advisors Retirement DNA San Diego World Trade Center Sartorius SecureDocs Scient Federal Credit Union Sharp Business Systems Sheppard Mullin Richter & Hampton Shred San Diego Signature Analytics Silicon Valley Bank SLM Group Sofinnova Ventures Sonceboz Corporation Square 1 Bank S Squared Executive Search Stradling Yocca Carlson & Rauth Savills Studley Sughrue Mion Synergy Corporate Housing Tata America International Technical Safety Services The Business Cleaning Company The HealthEd Group The Sandler Group Thomas, Mcnerney & Partners Time Warner Cable

T-Mobile USA Unifirst* United Parcel Service (UPS) VDP Direct Veolia Virgin America WCCT Global

* New Members from October 2014 to January 2015

10996 Torreyana Rd, Suite 200 San Diego, CA 92121-3021 www.Biocom.org Please send a change of address or subscription request to Sonali Vittachi at svittachi@Biocom.org.

Achieve Achieve Achieveprofessional professional professionalsuccess success success through through throughLife Life LifeScience Science Sciencecontinuing continuing continuing education education educationprograms. programs. programs.

Through cutting-edge workshops and events, UC San Diego Through Through cutting-edge cutting-edge workshops workshops and and events, events, UCUC San San Diego Diego Extension’s offers cutting-edge workshops and events that Extension’s Extension’s offers offers cutting-edge cutting-edge workshops workshops and and events events that that enhance skills development in critical Life Sciences occupations. enhance enhance skills skills development development in in critical critical Life Life Sciences Sciences occupations. occupations.

These programs attract both individuals and organizations alike.

These These programs programs attract attract both both individuals individuals and and organizations organizations alike. alike.

Medicinal Chemistry Intensive Program Medicinal Medicinal Chemistry Chemistry Intensive Intensive Program Program April 20-24, 2015

April April 20-24, 20-24, 2015 2015 This accelerated 1-week program focuses on the chemistry of drug molecules This This accelerated accelerated 1-week 1-week program program focuses focuses on the the chemistry chemistry ofthe of drug drug molecules molecules and drug action. It covers topics essential foron understanding multidisciand and drug drug action. action.

It covers It covers topics topics essential essential for for understanding understanding the the multidiscimultidisciplinary areas of medicinal chemistry as taught by a variety of experienced plinary plinary areas areas of and of medicinal medicinal chemistry chemistry as as taught taught

by Attendees by a variety a variety ofwill of experienced experienced pharmaceutical biotechnology professionals. leave with an pharmaceutical pharmaceutical andand biotechnology biotechnology professionals.

Attendees Attendees willwill leave leave with an an increased understanding of the key professionals. concepts in medicinal chemistry aswith related increased increased understanding understanding of of the the key key concepts concepts in medicinal in medicinal chemistry chemistry as as related related to drug discovery, a reduced barrier to creative contribution and discussion to to drug drug discovery, discovery, a reduced a reduced barrier barrier to creative creative contribution contribution and discussion discussion with biological collaborators, and antoincreased awareness ofand the meaning with with biological biological collaborators, andand an an increased increased awareness awareness of of thethe meaning meaning and relevance ofcollaborators, biological data and the limitations of its interpretation andand relevance relevance of of biological biological data data andand thethe limitations limitations of of its its interpretation interpretation

Mammalian Cell Culture Technology Mammalian Mammalian Cell Culture Culture Technology Technology June 3-5, 2015 Cell

June June 3-5, 3-5, 2015 2015 This 3-day workshop is designed to provide a deep understanding of the perforThisThis 3-day 3-day workshop workshop iscell designed is designed to provide provide athroughout deep a deep understanding understanding of and the of the perforperformance of mammalian culture to operations the product process mance mance mammalian of mammalian cell culture culture operations operations throughout throughout thethe product product and and process process life cycleoffrom process cell development to full scale manufacturing under current Good life life cycle cycle from from process process development development to to full full scale scale manufacturing manufacturing under under current current Good Manufacturing Practices. In addition to cell line and process development, thisGood Manufacturing Manufacturing Practices.

Practices.

In addition In addition to to cell cell line line and and process process development, development, this this workshop will explore insights into technology transfer, scale–up, and operational workshop workshop willwill explore explore insights intointo technology technology transfer, transfer, scale–up, and operational operational aspects.

State of the artinsights regulatory and quality practices willscale–up, play aand central role. aspects. aspects.

State State of the of the artart regulatory regulatory andand quality quality practices practices willwill play play a central a central role. role.

Microbial Fermentation Workshop Microbial Microbial Fermentation Fermentation Workshop Workshop August 12-14, 2015

August August 12-14, 12-14, 2015 2015 Taught by faculty and practitioners, this 3-day workshop is designed to provide Taught Taught by by faculty faculty and and practitioners, practitioners, thisthis 3-day 3-day workshop workshop is designed is designed to equip to provide provide a deep dive into bioreactor operations for microbial fermentations and you awith deep a deep dive dive into into bioreactor bioreactor operations operations for for microbial microbial fermentations fermentations and and equip equip the knowledge and practical skills needed to optimize your processes. youyou with with thethe knowledge knowledge and practical practical skills skills needed needed to to optimize optimize your processes. processes.

You will also explore and bioprocess simulation, economics and your modern techniques YouYou will also also explore explore bioprocess bioprocess simulation, simulation, economics economics andand modern modern techniques techniques used inwill applying process analytical technology in manufacturing. used used in applying in applying process process analytical analytical technology technology in manufacturing. in manufacturing.

Also included... Fermentor Demonstrations Also Also included... included...

Fermentor Fermentor Demonstrations by representatives from DCIDemonstrations Biolafitte! by by representatives representatives from from DCIDCI Biolafitte!

Biolafitte!

In Vitro Diagnostics Product Development InIn Vitro Diagnostics Product Product Development Development May 1Vitro & 2,Diagnostics 2015

May May 1 &1 2, & 2, 2015 2015 Explore the issues in moving an IVD product from concept to regulatory Explore Explore the the issues issues in moving in moving an an IVDIVD product product from from to to regulatory regulatory approval and market launch.

Although the focus isconcept onconcept IVD product development approval approval andand market market launch. launch.

Although Although thethe focus focus is on is on IVDIVD product development much of the material is applicable to product development in product otherdevelopment areas of much much of the of the material material is applicable is applicable to to product product development development in other in other areas areas of of biotechnology and pharmaceuticals. biotechnology biotechnology andand pharmaceuticals. pharmaceuticals.

• Understand the IVD product development process - beginning to end Understand • Understand thethe IVDIVD product development process process - beginning - beginning to to endend •• Learn the “language” ofproduct IVD development • Learn • Learn the the “language” “language” of of IVD IVD • Think like an IVD product developer • Think • Think likelike an an IVDIVD product product developer developer

(858) 534-9353 | unexbio@ucsd.edu | extension.ucsd.edu/lifesciences (858) (858)534-9353 534-9353| unexbio@ucsd.edu | unexbio@ucsd.edu| extension.ucsd.edu/lifesciences | extension.ucsd.edu/lifesciences